Cargando…
Assessing cost-effectiveness in the management of multiple sclerosis
Multiple sclerosis (MS) is one of the most common causes of neurological disability in young and middle-aged adults, with current prevalence rates estimated to be 30 per 100,000 populations. Women are approximately twice as susceptible as males, but males are more likely to have progressive disease....
Autores principales: | Phillips, Ceri J, Humphreys, Ioan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169986/ https://www.ncbi.nlm.nih.gov/pubmed/21935308 |
Ejemplares similares
-
The costs of traumatic brain injury: a literature review
por: Humphreys, Ioan, et al.
Publicado: (2013) -
Cost of managing patients with venous leg ulcers
por: Phillips, Ceri J., et al.
Publicado: (2020) -
Estimating the cost consequence of the early use of botulinum toxin
in post-stroke spasticity: Secondary analysis of a randomised controlled
trial
por: Lindsay, Cameron, et al.
Publicado: (2022) -
Estimating cost-effectiveness in public health: a summary of modelling and valuation methods
por: Marsh, Kevin, et al.
Publicado: (2012) -
Multiple Sclerosis and Pregnancy: Current Considerations
por: Buraga, Ioan, et al.
Publicado: (2014)